PCSK9 and musculoskeletal system disorder: Compared with statins/ezetimibe, PCSK9 inhibitors exhibited a lower reporting probability of adverse events associated with “nervous system disorders”, “psychiatric disorders” and “metabolism and nutrition disorders”, but mixed results for musculoskeletal disorders.